Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

777 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vascular protectants for the treatment of atherosclerosis.
Tardif JC, Grégoire J, Lavoie MA, L'Allier PL. Tardif JC, et al. Among authors: gregoire j. Expert Rev Cardiovasc Ther. 2003 Sep;1(3):385-92. doi: 10.1586/14779072.1.3.385. Expert Rev Cardiovasc Ther. 2003. PMID: 15030266 Review.
Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Tardif JC, Grégoire J, Schwartz L, Title L, Laramée L, Reeves F, Lespérance J, Bourassa MG, L'Allier PL, Glass M, Lambert J, Guertin MC; Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Tardif JC, et al. Among authors: gregoire j. Circulation. 2003 Feb 4;107(4):552-8. doi: 10.1161/01.cir.0000047525.58618.3c. Circulation. 2003. PMID: 12566365 Clinical Trial.
Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.
Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Anderson TJ, Reeves F, Title LM, Schampaert E, LeMay M, Lespérance J, Scott R, Guertin MC, Brennan ML, Hazen SL, Bertrand OF; CART-2 Investigators. Tardif JC, et al. Among authors: gregoire j. Atherosclerosis. 2008 Mar;197(1):480-6. doi: 10.1016/j.atherosclerosis.2006.11.039. Epub 2007 Jan 9. Atherosclerosis. 2008. PMID: 17214993 Clinical Trial.
Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.
Tardif JC, Grégoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, McLain R, Pressler ML, Ibrahim R, Lespérance J, Blue J, Heinonen T, Rodés-Cabau J; Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Tardif JC, et al. Among authors: gregoire j. Circulation. 2004 Nov 23;110(21):3372-7. doi: 10.1161/01.CIR.0000147777.12010.EF. Epub 2004 Nov 8. Circulation. 2004. PMID: 15533865 Clinical Trial.
777 results